Wire · opportunities
FDA Approves Iberdomide: A New Oral Paradigm in Multiple Myeloma Care
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 7 September 2026 · Fusion42 review
The FDA has approved oral iberdomide (Zenbexus), a first-in-class cereblon E3 ligase modulator, in combination with other therapies for adults with relapsed or refractory multiple myeloma who have had prior treatments. This introduces a potent oral treatment option in multiple myeloma care.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
The approval of iberdomide opens a new oral treatment pathway for multiple myeloma, making your product strategy potentially more complex if you compete in oncology drug combos. Expect shifts in patient medication adherence and dosing convenience to become factors in your development choices.
◆ Coverage
1 source · 7 Sep 2026
◆ Related on Wire
◆ Topics